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Abstract
Background: Treatment outcomes appear to be better for ovarian cancer (OC) patients carrying the BRCA1/2
germline mutation than for patients with sporadic OC. However, most published data are for North American,
British and Jewish populations. There have been very few studies on treatment outcomes in Central and Eastern
European patients with OC. The aim of this study was to analyse prognostic factors in Polish patients with
BRCA1-dependent OC (BRCA1-OC).
Methods: The records of patients with OC treated with surgery and chemotherapy at the Centre of Oncology in
Kraków, Poland, between 2004 and 2009 were reviewed. Based on family history, a group of 249 consecutive
patients fulfilling the criteria for risk of hereditary OC were selected and tested for the germline BRCA1 mutation.
Response to combination therapy (surgery and chemotherapy) in the BRCA1-OC group was assessed based on
clinical examination, imaging and serum CA125.
Results: Germline BRCA1 mutations were detected in 69 of the 249 patients, but three of these patients failed to
complete the study. Finally, 66 patients with BRCA1-OC were included in the study group. The median age of the
study patients was 49.5 years. All had undergone primary or interval cytoreductive surgery and chemotherapy.
Progression occurred in 48 (72.7 %) of the 66 patients and median time to progression was 20 months. The 5-year
overall survival rate in was 43.9 % and median survival time was 32.3 months. On multivariate analysis, the
endometrial subtype of OC and serum CA125 < 12.5 U/ml at the end of treatment were independent, positive
prognostic factors for 5-year overall survival.
Conclusion: Prognostic factors for favourable treatment outcomes in Polish patients with BRCA1-OC do not appear
to differ from those in patients with sporadic OC. The incidence of the endometrial subtype of OC was relatively
high (34.9 %) among women in the study. This was unexpected and has not been reported previously. This
subtype of OC was an independent prognostic factor for favourable treatment outcomes.
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Background
Many reports suggest that the outcomes of treatment for
ovarian cancer (OC) differ between patients who are car-
riers of BRCA1/2 mutations and patients with sporadic
OC (SOC). Most investigators report a better outcome for
patients with BRCA1/2-dependent OC (BRCA1/2-OC).
The BRCA1 and BRCA2 mutations are thought to cause
an impaired ability to repair DNA damage, and as a result,
BRCA1/2-OC is more sensitive than SOC to chemothera-
peutic drugs that act directly on the DNA double helix,
such as cisplatin and carboplatin [1, 2].
To date, most studies of the effect of BRCA1 and
BRCA2 mutations on OC treatment outcomes have been
carried out among American, British and Ashkenazi Jew-
ish women. The significance of germline mutation of the
BRCA2 gene in the Polish population has not yet been
established and, unlike mutation of the BRCA1 gene, it
is not routinely screened for among OC patients. Apart
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from one observational study in a small group of pa-
tients, there are no data on treatment outcomes for Cen-
tral and Eastern European women with BRCA1-OC [3].
It is possible that genetic diversity might lead to different
treatment outcomes in this population compared with pre-
viously studied populations. Moreover, there are limited
data available on prognostic factors among patients with
BRCA1-OC and it has not yet been determined whether
prognostic factors in patients with BRCA1-OC differ from
those in patients with SOC. Therefore, the aim of this
study was to analyse the prognostic factors for favourable
treatment outcomes in Polish patients with BRCA1-OC.
Methods
The records of all patients with OC treated with surgery
and chemotherapy at the Centre of Oncology in Kraków,
Poland, from 2004 to 2009 were reviewed. In total, there
were records for 1225 patients with OC diagnosed based
on examination of the surgical specimen or biopsy. From
the 1225 records, a group of 249 consecutive patients
who fulfilled the criteria of high risk for hereditary OC
based on family history were identified. After written, in-
formed consent was obtained blood was collected from
these 249 patients for BRCA1 mutation analysis. Exons 2,
5, 11 and 20 of the BRCA1 gene were analysed, and the
most frequent BRCA1 gene mutations among the Polish
population were searched for: 4153delA, 5382insC C61G,
185delAG and 3819del5. The DNA analysis was carried
out using denaturing high-performance liquid chromatog-
raphy (dHPLC), restriction fragment length polymorph-
ism (RFLP) and sequencing. The patients with BRCA1
mutations were selected as the study group. The study
was approved by the Ethics Committee of Maria Skło-
dowska-Curie Memorial Institute.
Response to combination therapy (surgery and chemo-
therapy) used to treat BRCA1-OC was assessed based on
clinical examination, imaging (Response Evaluation Cri-
teria in Solid Tumors [RECIST] criteria 1.0) and marker
analysis (serum CA125 concentration). Patients were
evaluated every three months for 2 years and every
6 months thereafter. All patients in the study group were
observed for at least 3 years or until death.
The effectiveness of treatment was evaluated according
to time to progression, defined as the period between
the beginning of treatment and clinical or imaging iden-
tification of recurrence of cancer, and 5-year overall sur-
vival from the beginning of treatment. The mean follow-
up period was 65 months. Survival probability was esti-
mated using the Kaplan–Meier method [4]. Peto’s log-
rank test was used to assess the statistical significance of
differences among the results [5]. The level of statistical
significance was set at p < 0.05. The Cox proportional
hazards model was used to assess the impact of selected
factors on patient survival [6].
Results and discussion
Among the 249 consecutive patients at high risk of her-
editary OC who were screened for germline mutation of
the BRCA1 gene, 69 (27.7 %) had mutations. However,
three women from this group did not complete the
treatment and were excluded from the study (one re-
fused chemotherapy and two died shortly after surgery
without having completed adjuvant treatment). There-
fore, the final study group included 66 patients with
BRCA1-OC. Before beginning treatment, all patients had
a histopathological diagnosis of OC. The median age
was 49.5 years (mean 48 years, range 23–75 years). All
study patients underwent planned combination therapy
and were further observed. They received from three to
nine courses of adjuvant therapy. Population, micro-
scopic and clinical characteristics of the 66 patients with
BRCA1-OC are presented in Table 1.
During follow-up, progression occurred in 48 (72.7 %)
of the study group. The mean time to progression was
26.2 months (median 20 months). The 5-year survival
rate was 43.9 % and the median survival time was
32.3 months. The overall survival Kaplan–Meier curve is
presented in Fig. 1. Table 2 shows a comparison of the
most significant publications on BRCA1/2-dependant
OC in terms of survival.
The population, microscopic and clinical factors that
were significant on univariate analysis are presented in
Table 3. Multivariate analysis showed a positive, statisti-
cally significant impact of the endometrial subtype of
OC and serum CA125 (<12.5 U/ml at the end of treat-
ment) on 5-year overall survival from BRCA1-OC. Both
of these factors were independent prognostic factors for
5-year overall survival (Table 4).
The composition of the study group did not differ
from previously published studies in terms of popula-
tion, histopathologic and clinical factors. The number of
BRCA1-OC patients in the present study was relatively
high compared to previous studies, most of which in-
cluded 13–43 patients, with only a few recruiting higher
numbers of 88–245 patients. Among these previous
studies, a small number evaluated the clinical features
and outcome of patients with BRCA1-OC separately
from patients with BRCA2-OC. However, these studies
were conducted among Jewish, American and Western
European populations, which seem to be genetically dif-
ferent from the Polish population [7–9].
Consistent with previous reports, the serous subtype
of OC was predominant among the study patients (n =
27, 40.9 %). The percentage of the serous subtype re-
ported in the literature varies widely from 25 to 93 %,
which might be related to the size of patient groups.
However, in contrast to previous reports, the percentage
of patients with the endometrial subtype of OC (34.9 %)
was high in the present study, whereas previous studies
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have found that 14 % or less of patients with BRCA1-
OC have this subtype [10]. Interestingly, another Polish
population analysis of patients with BRCA1-OC reported
an unusually high percentage of mucinous cancers
(17 %). However, that study was small with only 18 pa-
tients [3]. Both findings are unusual because somatic
tumour mutations of the BRCA1 gene are rare in endo-
metrial and mucinous subtypes of OC.
Prognostic factors in patients with BRCA1-OC
To date, few studies have investigated prognostic factors
associated with BRCA1/2-OC. Most research has focussed
on differences in treatment outcomes between OC pa-
tients with and without BRCA1/2 mutations. Further-
more, few studies have looked at differences in prognostic
factors between patients with SOC and BRCA1/2-OC.
The strongest prognostic factor for treatment outcomes
in patients with SOC is the FIGO cancer stage. On univar-
iate analysis in the present study, the FIGO cancer stage
was a prognostic factor for 5-year overall survival of
BRCA1-OC patients. However, this was not confirmed in
the multivariate analysis, possibly as a result of the small
number of patients with early-stage disease (4 patients
had stage I disease and 8 had stage II disease).
Similar to SOC patients, in the present study opti-
mal surgical cytoreduction (remnants after surgery
≤1 cm) had a positive prognostic impact on survival
in patients with BRCA1-OC. The difference in the 5-
year survival rate between patients with and without
optimal surgical cytoreduction was 30 %, which is
similar to that reported in the literature for SOC [11, 12].
Only one previous study investigated the impact of
the extent of surgical cytoreduction on survival in pa-
tients with BRCA1/2-OC [10]. That study identified a
statistically significant higher risk of death among pa-
tients with surgery that was not considered complete,
with a hazard ratio (HR) = 1.48 on multivariate ana-
lysis. However, in the present study, the prognostic
value of cytoreduction was not confirmed on multi-
variate analysis, probably because of the limited num-
ber of cases.
Table 1 Population, microscopic and clinical characteristics of
BRCA1-OC patients
No. of
patients
Percent
Population, microscopic and clinical characteristics 66 100
Age
- ≤ 50 years 34 51.5
- > 50 years 32 48.5
Menopause
- yes 28 42.4
- no 38 57.6
No. of births
- 0 10 15.2
- 1 27 40.9
- ≥2 29 43.9
Family history
- 1st degree relatives with ovarian cancer 8 12.1
- 1st degree relatives with breast cancer 17 25.8
Coexisting breast cancer
- yes 9 13.6
Type of BRCA1 gene mutation
-C61G 31 47
- 5382insC 21 31.8
- 4153delAG 6 9.1
- 189delAG 4 6.1
- 3819del5 2 3
- IVS20 + 60ins12 1 1.5
- 4158A > G 1 1.5
Grading of the tumor
- G1 2 2.7
- G2 18 27.3
- G3 46 70
Histological type
- serous 27 40.9
- endometrial 23 34.9
- undifferentiated 8 12.1
- mucous 4 6.1
- clear cell 2 3
- mezonefroid 2 3
Staging FIGO (2009)
- I 4 6.1
- II 11 16.7
- III 50 75.7
- IV 1 1.5
Cytoreduction
- primary 44 66.7
Table 1 Population, microscopic and clinical characteristics of
BRCA1-OC patients (Continued)
- interval 22 33.3
The overall extent of cytoreduction
- optimal 34 51.5
- suboptimal 32 48.5
The average concentration of CA125 at the
beginning of treatment
1113 U/
ml
The average concentration of CA125 at the end of
treatment
71 U/ml
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Of the patients with BRCA1-OC in the present
study, nine (13.6 %) patients had been previously
treated for breast cancer, and had achieved a
complete and long-lasting remission. In all nine
patients, the breast cancer was treated with surgery
and one line of anthracycline-based chemotherapy.
None of the patients had received platinum agents.
Imaging, clinical findings, serum markers and
immunohistochemical analysis of ovarian tumours
confirmed that all nine patients had primary OC ra-
ther than secondary breast cancer. The 5-year survival
rate in this group was significantly lower compared
with the other BRCA1-OC patients (11.1 % vs.
49.1 %, respectively). It should be noted that progres-
sion of OC can mask the recurrence of breast cancer
resulting in poorer outcomes.
Fig. 1 Overall survival of patients with BRCA1-OC
Table 2 Comparison of long-term outcome in patients with BRCA-OC
Author, year of publication No. of patients Population Overall 5-year survival Median survival
Rubin 1996 [23] 53 BRCA1/2-OC ~60 %a ~80 monthsa
Pharoah 1999 [7] 127 BRCA1/2-OC 21 % 20,6 months
Boyd 2000 [10] 67 BRCA1-OC ~50 %a ~60 monthsa
Ramus 2001 [24] 15 BRCA1-OC ~25 %a 52 months
Cass 2003 [11] 33 BRCA1/2-OC 65 % 91 months
Majdak 2005b [3] 18 BRCA1-OC ~33 %a ~28 monthsa
Chetrit 2008 [8] 213 BRCA1/2-OC 46 % 53,7 months
Tan 2008 [25] 22 BRCA1/2-OC ~65 %a 8,4 years
Kringen 2005 [26] 30 BRCA1/2-OC 33,3 % -
Lacour 2011 [27] 95 BRCA1/2-OC ~25 %a 101,7 months
Hyman 2012 [9] 30 BRCA1-OC ~60 %a 6 years
Vencken 2013 [28] 245 BRCA1-OC 62 % 6 years
Bolton 2012 [29] 909 BRCA1-OC 44 % 4,6 years
Own material 66 BRCA1-OC 43,9 % 32,3 months
a Data extrapolated from the Kaplan-Meier curves
b Polish patients population
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Among patients with BRCA1-OC, Chetrit et al.
found that the serous subtype of OC was associated
with a poorer prognosis compared to the non-serous
subtype (5-year overall survival rate of 44.9 % vs.
50 %, respectively), and poorly differentiated tumours
were associated with a poorer prognosis than well dif-
ferentiated and moderately differentiated subtypes (5-
year overall survival rate of 45.4 % vs. 55 %, respect-
ively) [8]. In terms of the importance of microscopic
subtypes of OC on prognosis, the results of the
present study agreed with previous studies on SOC.
On univariate analysis the endometrial subtype of OC
was associated with a better prognosis compared to
the serous subtype of OC, and the poorest prognosis
was associated with the undifferentiated adenocarcin-
oma subtype. The numbers of patients in the present
study with mucous, clear-cell and mesonephroid types
of BRCA1-OC were too small to draw statistical con-
clusions. Endometrial tumours are more likely to de-
velop in the pelvis without spread to the upper
abdomen and they are more likely to be diagnosed at
an early stage. Similarly, on multivariate analysis, a
statistically significant positive impact on the 5-year
overall survival was associated with the endometrial
subtype of the OC. The impact of histological grade
(G) on treatment outcomes was not statistically sig-
nificant on univariate or multivariate analysis.
The serum CA125, both at the beginning of treatment
and after treatment completion, is a widely confirmed
prognostic factor in patients with OC [13–20]. For pa-
tients with BRCA1-OC, the reported average serum
CA125 before treatment ranges from 445 U/ml to 824
U/ml [11, 21, 22]. However, there are no data on serum
CA125 levels at the end of treatment. In the present
study, the average serum CA125 in patients with
BRCA1-OC was 113 U/ml and 71 U/ml before and after
treatment, respectively. No previous studies have re-
ported that serum CA125 levels were a prognostic factor
in patients with BRCA1/2-OC. However, on univariate
analysis in the present study a relatively low serum
CA125 at the beginning of treatment and after treatment
was associated with better prognosis (67.7 % vs. 22.9 %
5-year overall survival for serum CA125 ≤ 285.5 U/ml vs.
>285.5 U/ml at the beginning of treatment, and 64.7 %
vs. 31.8 % 5-year overall survival for serum CA125 of
≤12.5 U/ml vs. >12.5 U/ml after treatment).
Conclusions
Prognostic factors for treatment outcomes in Polish pa-
tients with BRCA1-OC do not appear to differ from
Table 3 Results of treatment of patients with BRCA1-OC
depending on the population, microscopic and clinical
characteristics
Population, microscopic and
clinical characteristics
No. of
patients
5-year overall
survival
No. of
patients
%
The number of patients with BRCA1
gene mutation
66 29 43.9
a Coexisting neoplasms
- no 57 28 49.1
- breast cancer 9 1 11.1
a The total extent of cytoreduction
- optimal 34 20 58.8
- suboptimal 32 9 28.1
a Staging FIGO (2009)
- I 4 4 100.0
- II 8 5 62.5
- III 50 19 38.0
- IV 4 1 25.0
a Histological type
- serous 27 11 40.7
- endometrial 23 14 60.9
- undifferentiated 8 1 12.5
- mucous 4 2 50.0
- clear cell 2 1 50.0
- mezonefroid 2 0 0
a CA125 concentration at the beginning
of treatment
- < 285,5 31 21 67.7
- ≥285,5 35 8 22.9
a CA125 concentration at the end
of treatment
- <12,5 34 22 64.7
- ≥12,5 22 7 31.8
a Statistically significant differences, log rank test, p <0.05
Table 4 Results of the multivariate analysis of prognostic factors in the group of 66 patients with BRCA1-OC
Variable Variant Relative risk (RR) Confidence interval p value
Histological type Undifferentiated adenocarcinoma 39,29 2,07–743,35 p = 0.014
Serous adenocarcinoma 1
Histological type Endometrial adenocarcinoma 0,2 0,04–0,85 p = 0.03
Serous adenocarcinoma 1
Level of CA125 at the end of treatment <12,5 U/ml 0,23 0,07–0,69 p = 0.01
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those in patients with SOC. The incidence of the endo-
metrial subtype of OC was relatively high, which is a
new finding not previously reported in the literature.
This form of OC was also an independent, positive prog-
nostic factor on multivariate analysis.
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